GleamWall
中文EN

IMDX Insight Molecular Diagnostics Inc.

In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 1642380 · Fiscal year ends 12/31

Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY520.9%
TTM net income YoY-40.9%
TTM EPS YoY27.5%
Revenue 3-yr CAGR1.0%
Net income 3-yr CAGR—

Margins

Gross margin54.5%
Operating margin-1,392.9%
Net margin-1,380.7%
FCF margin-540.3%
EBITDA margin-1,343.0%

Returns

ROE-23,603.1%
ROA-106.5%
ROIC (approx.)—
Asset turnover0.08x

Leverage & solvency

Liabilities / assets120.9%
Debt / equity—
Current ratio2.79x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.36x
Accruals ratio-68.2%
Payout ratio—
Capex / revenue43.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$4.05M$1.88M
Cost of revenue$1.75M$1.05M
Gross profit$2.30M$740,000
R&D expense$15.90M$9.84M
SG&A expense$10.63M$10.20M
Operating income-$51.12M-$61.04M
Pretax income—-$60.66M
Income tax$0$0
Net income-$50.22M-$60.66M
EBITDA-$48.93M-$59.48M
EPS (basic)-1.65-4.66
EPS (diluted)-1.65-4.66
Weighted avg. shares (diluted)30.48M13.07M
Banking
Net interest income-$109,000-$84,000
Balance sheet
Cash & equivalents$11.58M$8.64M
Receivables$1.13M$1.61M
Inventory$446,000$410,000
Current assets$15.31M$11.76M
PP&E, net$6.43M$6.32M
Intangibles$0$14.61M
Total assets$25.76M$35.08M
Current liabilities$12.07M$7.28M
Total liabilities$57.22M$47.35M
Shareholders' equity-$31.46M-$12.27M
Shares outstanding28.68M17.45M
Cash flow statement
Operating cash flow-$22.18M-$20.69M
Capital expenditure$3.19M$516,000
Free cash flow-$25.37M-$21.20M
Investing cash flow-$3.19M-$512,000
Financing cash flow$28.07M$20.43M
Depreciation & amortization$2.20M$1.56M
Stock-based compensation$2.22M$1.75M

Free plan shows the latest 2 periods; Pro shows all 12 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.